04.20 (Åä) 15:51
·Î±×ÀÎ
ȸ¿ø°¡ÀÔ
±¤°í¹®ÀÇ
µ¶ÀÚÁ¦º¸
񃯇
񃯇
ÀǾàÇ°
³¹¾Ë½Äº°
µ¥Àϸ®ÆÊ Live Search
´Ý±â
´º½º
Àüü±â»ç
Á¤Ã¥ · ¹ý·ü
Á¦¾à · ¹ÙÀÌ¿À
¾à±¹ · º´¿ø
Ä«µå´º½º
ÆÊTV
À̽´¿µ»ó
ºÎÀۿ븮Æ÷Æ®
1µî ¾à±¹À» ã¾Æ¼
½ºÆ¿ÄÆ ¿µ»ó
¿ÀÇǴϾð
Àü¹®°¡Ä®·³
µ¥½ºÅ©½Ã¼±
±âÀÚÀÇ ´«
µ¶ÀÚ±â°í
English
Policy
Opinion
Company
Product
Interview
TVÆʵµ¶ó
ÆÊTube
ÆʼîÇÎ
³ª´Â¾à»ç´Ù
Æʵå¶ó¸¶
ÆʾÆÄ«µ¥¹Ì
Á¦Ç°°ÁÂ
Çмú°ÁÂ
°æ¿µ°ÁÂ
Ä¿¹Â´ÏƼ
Æʸ®Äí¸£Æ®
ä¿ëÁ¤º¸
PHARMARCY
ÀÎÀçÁ¤º¸
DPºÎµ¿»ê
¾à±¹»ó´ã¼Ò
¾à±¹´ëÃâ
¼¼¹«»ó´ã
¹ý·ü»ó´ã
¾à±¹ÈÀåÇ°
¾à±¹°æ¿µ
¾à»ç´ëÃâ
ÀǾàÀÚ·á½Ç
ÀǾàÇàÁ¤
¾à»ç¾à±¹
ÀǷẴ¿ø
Á¦¾àÀ¯Åë
º¸µµÀÚ·á
ÆÊÆ÷ÀÎÆ®¸ô
À¯¸Ó · ¸¸È
ÀÎ»ç · ºÎÀ½
¾à±¹ÀåÅÍ
ȸ»ç¼Ò°³
ȸ¿ø°¡ÀÔ
±¤°í¹®ÀÇ
»ç¾÷Á¦ÈÞ
ÀÎÅͳݽŹ®À±¸®°·É
µ¶ÀÚÁ¦º¸
±âÀÚÀ±¸®°·É
ÀÚÀ²¼¾à¼
¿ø°ÝÁö¿ø¿äû
Event & ¼¼¹Ì³ª
´º½º
English
ÆÊTV
¿ÀÇǴϾð
Æʸ®Äí¸£Æ®
DPºÎµ¿»ê
TVÆʵµ¶ó
ÆÊÆ÷ÀÎÆ®¸ô
ÆʾÆÄ«µ¥¹Ì
Event
ÀÇ´ëÁõ¿ø 2õ¸í º® ±ü Á¤ºÎ¡¦ÀÇÁ¤ °¥µî Ãⱸ 㳪
ÀÇ´ëÁõ¿ø 2õ¸í ±ÁÈù Á¤ºÎ¡¦"50~100% ÀÚÀ²¸ðÁý Çã¿ë"
Á¤ºÎ, ±¹¸³´ë °ÇÀÇ ¼ö¿ë °¡´Ú¡¦ÀÇ´ë Áõ¿ø Ãà¼ÒµÉ µí
"ó¹æ 30% ÁÙ°í, Àå±âó¹æ ´Ã°í"...Èçµé¸®´Â '¹®Àü ºÒÆÐ'
"6°³¿ù¡¤1³âÄ¡ ¾à Ÿ°¡°í ÀϺΠÀü¿øµµ" ³Ã´ãÇÑ ¹ÝÀÀ
ÀÇ´ëÁõ¿ø 2õ¸í ±ÁÈù Á¤ºÎ¡¦"50~100% ÀÚÀ²¸ðÁý Çã¿ë"
Á¤ºÎ, ±¹¸³´ë °ÇÀÇ ¼ö¿ë °¡´Ú¡¦ÀÇ´ë Áõ¿ø Ãà¼ÒµÉ µí
6°³ ±¹¸³´ë "ÀÇ´ëÁ¤¿ø 50~100% ÀÚÀ²Àû Áõ¿ø Çã¿ëÀ»"
½Ã¹ü»ç¾÷ µüÁö ¶¼´Â °ø°ø½É¾ß¾à±¹¡¦ÁöÁ¤ ±âÁØ °ü°Ç
¸ÅÃâ 1Á¶ ÀÌ»ó 10³â»õ '1¡æ5°÷'...´ëÇü À¯Åë¾÷ü ¼Ó¼Ó µîÀå
'»óÀ塤±â¼úÀÌÀü¡¤Çã°¡'¡¦µ¿±¸¹ÙÀÌ¿ÀÀÇ ÅõÀÚ±â¾÷ ¼±°ßÁö¸í
GMP ½ÇÅÂÁ¶»ç °á°ú °ø°³ 2³â...±¹³»»ç 31°÷ µî·Ï
¹ý¿ø ÆÇ°á È®Á¤ ¿µÇ⡦HKÀ̳뿣, 98Ç°¸ñ ¾à°¡ÀÎÇÏ
SELECT COUNT(*) FROM Poll_Vote WHERE Poll_ID='210' AND Example_ID='415' AND Poll_Vote.voteType ='V'
SELECT COUNT(*) FROM Poll_Vote WHERE Poll_ID='210' AND Example_ID='416' AND Poll_Vote.voteType ='V'
Issue & Poll
´ëÇüº´¿ø ½ò¸² ÇØ¼Ò °¡´ÉÇÒ±î?
½ÇÈ¿¼º ¾ø´Ù
VS.
½ò¸²Çö»ó ÇØ¼Ò °¡´É
ÅõÇ¥ & ÀÇ°ß¾²±â
DPÃÊ´ë¼®
À̾籸 µ¿¼ºÁ¦¾à ´ëÇ¥
´«¿¡ ¶ç´Â CF
½Å½ÅÁ¦¾à-¾Æ·º½º
¹ÌÇâ¾àÇ°-¶óÄ«·çÆ®
ÆÊTV
ºñ´ë¸é¡¤¾à¹è¼Û¡¤¾à°¡¡¤°Çº¸±îÁö...Á¤Ã¥ ÃßÁø Ÿ°Ý ºÒ°¡ÇÇ
ÆÊTalk
½ºÅ×·ÎÀ̵å Àå±â»ç¿ë ºÎÀÛ¿ë°ú ¾à±¹ »ó´ã¹ýÀº?
¿À´ÃÀÇ
ÇÖ´º½º
1
Àü´ã¾à±¹, Äڷγª Ä¡·áÁ¦ º»Àκδã±Ý 5¸¸¿ø ¹Þ¾Æ¾ß
2
"ó¹æ 30% ÁÙ°í, Àå±âó¹æ ´Ã°í"...Èçµé¸®´Â '¹®Àü ºÒÆÐ'
3
ÀÇ´ëÁõ¿ø 2õ¸í º® ±ü Á¤ºÎ¡¦ÀÇÁ¤ °¥µî Ãⱸ 㳪
4
½Ã¹ü»ç¾÷ µüÁö ¶¼´Â °ø°ø½É¾ß¾à±¹¡¦ÁöÁ¤ ±âÁØ °ü°Ç
5
¸ÅÃâ 1Á¶ ÀÌ»ó 10³â»õ '1¡æ5°÷'...´ëÇü À¯Åë¾÷ü ¼Ó¼Ó µîÀå
6
PPI+Á¦»êÁ¦ ±ÞÆØ⡦¶óº£µà¿À '²±Ãæ'¡¤¿¡¼Òµà¿À 'ÁÖÃã'
7
'»óÀ塤±â¼úÀÌÀü¡¤Çã°¡'¡¦µ¿±¸¹ÙÀÌ¿ÀÀÇ ÅõÀÚ±â¾÷ ¼±°ßÁö¸í
8
"½Å±Ô¹°Áú Ž»ö¡¤Æ¯Çã±îÁö"...½Å¾à ²Þ²Ù´Â ½ÅÁø ¾àÇÐÀÚµé
9
¹ý¿ø ÆÇ°á È®Á¤ ¿µÇ⡦HKÀ̳뿣, 98Ç°¸ñ ¾à°¡ÀÎÇÏ
10
¾Æ½ºÆ®¶óÁ¦³×Ä«, ½Ã½Å°æô¼ö¿° ¹üÁÖÁúȯ °æÀï·Â È®´ë È°¹ß
PPI+Á¦»êÁ¦ ±ÞÆØ⡦¶óº£µà¿À '²±Ãæ'¡¤¿¡¼Òµà¿À 'ÁÖÃã'
1ºÐ±â 'PPI+Á¦»êÁ¦' ó¹æ½ÇÀû 174¾ï¡¦À¯³ªÀÌƼµå ¾àÁø
º¹ÇÕÁ¦ Çã°¡ º¿¹°...¿¡Á¦+¾ÆÅ丣¹Ù, PPI+Á¦»êÁ¦ Á¶ÇÕ
¶óº£ÇÁ¶óÁ¹+Á¦»êÁ¦ »õ Á¶ÇÕ µîÀ塦°æÀï ºÒºÙÀ»±î
'PPI+Á¦»êÁ¦' ½ÃÀå Ȱ¦...¶óº£µà¿À, ¿¡¼Òµà¿À Ãß¿ù
Àü´ã¾à±¹, Äڷγª Ä¡·áÁ¦ º»Àκδã±Ý 5¸¸¿ø ¹Þ¾Æ¾ß
¾Æ½ºÆ®¶óÁ¦³×Ä«, ½Ã½Å°æô¼ö¿° ¹üÁÖÁúȯ °æÀï·Â È®´ë È°¹ß
Çѹ̻çÀ̾ð½º, ³ë¿ë°© Àü »çÀå ºÎȸÀåÀ¸·Î ¿µÀÔ
ÀÇ´ëÁõ¿ø 2õ¸í ±ÁÈù Á¤ºÎ¡¦"50~100% ÀÚÀ²¸ðÁý Çã¿ë"
¿©±ä µÇ°í, Àú±ä ¾È µÇ°í¡¦°³ºÀ ¸¶¾à¡¤ÇâÁ¤¾à ¹ÝÇ° ³í¶õ
"½Å±Ô¹°Áú Ž»ö¡¤Æ¯Çã±îÁö"...½Å¾à ²Þ²Ù´Â ½ÅÁø ¾àÇÐÀÚµé
ÀÎÅͺä | ¾àÇÐȸ ¹Ì·¡¾àÇпì¼ö³í¹®»ó ¼ö»óÀÚµé
"ÀÓ»ó¾à¹« ¹ßÀü¿¡ ¾à´ë-º´¿ø Çù·Â...º¸»ó¡¤Áö¿øÀº ºÎÀç"
"¾àÇבּ¸ ÈļӼ¼´ë¿¡ ÅõÀÚ...»ê¾÷°è¿Í ½Å¾à ²ÉÇÇ¿ï °Í"
"¾àÇÐÀÇ ¹àÀº ¹Ì·¡ ºÃ´Ù"...1500¸í ¸ô¸° ¾àÇÐȸ Çмú´ëȸ
¾Ë¸é µ· µÇ´Â ¾à±¹ ¼¼¹«°ÀÇ...22ÀÏ Àú³á 7½Ã »ýÁß°è
ÆÊÅäÅ©
½ºÅ×·ÎÀ̵å Àå±â»ç¿ë ºÎÀÛ¿ë°ú ¾à±¹ »ó´ã¹ýÀº?
¾ÆÅäÇÇ¾à ¾ÆÆ®¶öÀÚ, 5¿ù ±Þ¿©¡¦°ñ´Ù°øÁõ¾à ±Þ¿© È®´ë
JWÁß¿Ü °í¿ë·® öºÐÁÖ»ç 'Æ丰Á§Æ®' ³»´Þ ±Þ¿©µîÀç
Àü±¹ ¾à±¹ 2¸¸5000°÷ µ¹ÆÄ...¸Å³â 2%´ë Áõ°¡¼¼
À̹ø¿£ ȯÀÚ¾ÈÀü°ü¸® ȨÇÇ ¸ÔÅ롦¾à¹° ºÎÀÛ¿ë º¸°í ½ºÅé
"5ÀÎ ¹Ì¸¸ ¾à±¹, 30ÀÏ Àü¿¡ ¿¹°íÇÏ¸é ºÎ´çÇØ°í ¾Æ³Ä"
½Ã¹Ð·¯ ħÅõ¿¡µµ ö¿Ë¼º...È޹̶ó ¹Ì±¹ Á¡À¯À² 96%
"ÀÓ»ó¾à¹« ¹ßÀü¿¡ ¾à´ë-º´¿ø Çù·Â...º¸»ó¡¤Áö¿øÀº ºÎÀç"
µðÁöÅÐÄ¡·á±â±â 3¡¤4È£ Çã°¡...ÀÎÁöÄ¡·á¡¤È£ÈíÀçÈ° S/W
ÀÓÇöÅà "ÀÇ·á°ø¹é ÇØ¼Ò ÁÖÀåÇÏ´ø ÇÑÀÇÇù ¹«¹¬ºÎ´ä"
Á¤ºÎ, ±¹¸³´ë °ÇÀÇ ¼ö¿ë °¡´Ú¡¦ÀÇ´ë Áõ¿ø Ãà¼ÒµÉ µí
6°³ ±¹¸³´ë "ÀÇ´ëÁ¤¿ø 50~100% ÀÚÀ²Àû Áõ¿ø Çã¿ëÀ»"
"°¡¶àÀ̳ª Èûµçµ¥"¡¦CRO, ÀÇ·á°ø¹é Àå±âÈ¿¡ '¹ß µ¿µ¿'
AAP 16°³¿ù¸¸¿¡ ¾à°¡ÀÎÇÏ...Á¦¾à»ç ¼ö½Ê¾ï ¼Õ½Ç ¿¹°í
¸ÅÃâ ÄöÅÒÁ¡ÇÁ ½ÇÇö À§ÇÑ Á¦¾à ¿À³Ê3¼¼ÀÇ °æ¿µÈµÎ´Â
Á¤ºÎ, ¹ÙÀ̵ç ÇàÁ¤¸í·É¡¤IRA¹ý, Á¦¾à»ê¾÷ Ãæ°ÝÆÄ ºÐ¼® Âø¼ö
½Å¼³ Çõ½Å½Å¾àÇаú ÇѾç´ë À¯·Â...±³À°ºÎ ÀÌ´Þ ¹ßÇ¥
Å°Æ®·ç´Ù ±Þ¿©È®´ë, ³×¹ø° ¾ÏÁú½É ºÒ¹ß ÀÇ¹Ì¿Í ¹è°æÀº
Çõ½ÅÁ¦Ç° ½Å¼Ó ½ÃÀåÁøÀÔ Áö¿ø 'ºê¸´Áö'¸¦ ¾Æ½Ã³ª¿ä?
¾¾Æ¼¾¾¹ÙÀÌ¿À-Æĸ¶¸®¼Ä¡ 'ÁÖ°¡¡¤½ÇÀû¡¤R&D' Èñºñ
'¾Öµå¼¼Æ®¸®½º' IPS Á¡¼ö »èÁ¦¡¦È¯ÀÚ ¿°¿ø ÇØ¼Ò Ã»½ÅÈ£
"¾àÇבּ¸ ÈļӼ¼´ë¿¡ ÅõÀÚ...»ê¾÷°è¿Í ½Å¾à ²ÉÇÇ¿ï °Í"
Àå±âÈµÈ ÀÇ·á´ë¶õ¿¡ 'PA °£È£»ç' Á¦µµÈ ±Þ¹°»ì
"Ç÷£B ´ëü ¹º°¡"¡¦ÇѾà»ç ¹®Á¦¿¡ ´ä´äÇÑ ¾à»çµé
'¼øÁ¶·Î¿î ¾ÈÂø'...´ë¿õ 'Æå¼öŬ·ç' 1ºÐ±â ó¹æ¾× 170¾ï
°Ç¹°ÁÖ ¾à±¹ ±Ç¸®±Ý ȸ¼ö ¹æÇØ, ¾î¶»°Ô ´ëÀÀÇØ¾ß Çϳª
¼Ûµµ/¿À¼Û/ºÎ»ê Á¦Á¶/Ç°Áú°ü¸® ¾à»ç ¸ðÁý
Medical ¹× Clinical °¢ ºÎ¹® ä¿ë
Ç°Áú°ü¸®¾à»ç / Á¦Á¶°ü¸®¾à»ç ä¿ë
2024³â ÇÑ¹Ì±×·ì »ó¹Ý±â Çѹ̱׷ì ÀÎÀç¸ðÁý [Á¤±â°øä]
ÃæºÏ ÃæÁֽà µµ¸Å °ü¸® ¾à»ç ¸ðÁý
º¸°ü¼Ò Ç°Áú°ü¸®¾à»ç
¼¿Æ®¸®¿Â 2024³â 1Â÷ ½ÅÀÔ/°æ·Â ¼ö½Ãä¿ë
[CSL Behring] Medical Representative
MSL (Medical Science Liason)_Á¤±ÔÁ÷ ¸ðÁý
(´ëÀü/Ãæû) ¿µ¾÷ºÎ °æ·ÂÁ÷(ÁÖÀÓ~´ë¸®±Þ) ¸ðÁý
[»ï¿ø¾àÇ° ¿ï»êÁöÁ¡] °ü¸®¾à»ç´Ô ¸ðÁý°ø°í
JW±×·ì 24³â 2Â÷ ¼ö½Ãä¿ë
2024³â Á¦3Â÷(¹ÌÀÀ½ÃºÐ¾ß)ä¿ë ¿¬Àå ¹× Àç°ø°í
[CSL Behring] Marketing Product Manager
¾àÁ¤¿ø ¿î¿µ ÇÁ·Î±×·¥ÀÌ ºÒ¾ÈÇÏ´Ù
±âÀÚÀÇ ´«
°Çý°æ
+
¾à±¹ ÀÏ¹Ý¾à ³¸Å¿Í Â÷º°È Àü·«
±âÀÚÀÇ ´«
Á¤ÈïÁØ
+
ºÒ¼ø¹° ¼Ò¼Û°ú Á¤Ã¥ ¹Ý¼º
µ¥½ºÅ©½Ã¼±
õ½ÂÇö
+
GMP Ãë¼Ò óºÐ°ú ¾ö¹úÁÖÀÇÀÇ ÇÑ°è
±âÀÚÀÇ ´«
±èÁø±¸
+
ºÎÀ½
Á¤¸íÈ£ ¹ÙÀ̳ؽº ȸÀå ¸ðÄ£
ºÎÀ½
ÀÌÇѳª °æ±âµµ¾à È«º¸À§¿øÀå ½Ã¸ð
ÈÃË
È«»ó¿Ï ¹ÙÀÌ¿ÀÆĸ¶ ºÎ»çÀå µþ(4/28)
ºÎÀ½
±èÀ¯¼÷ Çѱ¹¾Öºêºñ ´ë¿ÜÇù·ÂºÎ Àü¹« ¸ðÄ£
ºÎÀ½
±èºÎ¼· Çö´ëº´¿øÀå ºÎÄ£
ºÎÀ½
¹Ú¿ø±³ YS»ý¸í°úÇÐ Àü¹«ÀÌ»ç ¸ðÄ£
µ¿Á¤
±è¿ëÀç ±³¼ö, ´ëÇѳúÁ¹ÁßÇÐȸÀå ¼±Ãâ
ºÎÀ½
±è¹Ì¿Á °æºÏ ¾Èµ¿ ´Ù³ª¾à±¹ ¾à»ç º»ÀÎ
ÀÎÅͺä
"¸Ó¸´¼Ó ½ÃÇÑÆøź '³úµ¿¸Æ·ù' ȯÀÚ¸¶´Ù Ä¡·á¹ý ´Þ¶ó"
À±º°Èñ ÀÇÁ¤ºÎÀ»Áö´ëº´¿ø ½Å°æ¿Ü°ú ±³¼ö
¿À´ÃÀÇ ´Ü½Å
Àüü
|
Á¤Ã¥°ú ¹ý·ü
|
Á¦¾à¡¤¹ÙÀÌ¿À
|
º´¿ø¡¤¾à±¹
"A9 ¸ðµÎ µîÀçµÈ ¿¢½ºÆ÷ºñ¿À, ±¹³» Á¶¼ÓÈ÷ µîÀçµÅ¾ß"
¼ºµ¿±¸¾à, ÇѾ౹ °³¼³ µû¸¥ ÀÚÀ²ÁöµµÁ¡°Ë °È
ÃÖ±¤ÈÆ ´ë¾àȸÀå, ´ö¼º¾à´ë¼ '¾à»çÀÇ »çȸÀû ¿ªÇÒ' Ư°
ÀÓÁ¾À± °øµ¿´ëÇ¥ 'ÀÇ·áÇõ½ÅÀ§¿øȸ' ù ¼¼¹Ì³ª °³ÃÖ
µ¿¼ºÁ¦¾à, º£Æ®³² ÇϳëÀÌ ºäƼÄÉ¾î ¿¢½ºÆ÷ Âü°¡
"A9 ¸ðµÎ µîÀçµÈ ¿¢½ºÆ÷ºñ¿À, ±¹³» Á¶¼ÓÈ÷ µîÀçµÅ¾ß"
½Ä¾àó, ±ÔÁ¦°úÇÐ Çõ½ÅÆ÷·³...»ê‧ÇÐ‧°ü Çù·Â¾È ³íÀÇ
°æÀνľàûÀå, ¿ø·á¾à Áö¿ø ¼ÒÅë...À¯ÇÑÈÇÐ ¹æ¹®
»ê¾÷ºÎ, ¿ì¼ö ¹ÙÀÌ¿À±â¾÷ ÅõÀÚÀ¯Ä¡ Áö¿ø¿¡ ÆȰȾî
¹ÙÀÌ¿ÀÄÚ¸®¾Æ ÄÁÆÛ·±½º, ³»´Þ 8~10ÀÏ °³ÃÖ
ÀÓÁ¾À± °øµ¿´ëÇ¥ 'ÀÇ·áÇõ½ÅÀ§¿øȸ' ù ¼¼¹Ì³ª °³ÃÖ
µ¿¼ºÁ¦¾à, º£Æ®³² ÇϳëÀÌ ºäƼÄÉ¾î ¿¢½ºÆ÷ Âü°¡
¾¾Æ¼¾¾¹ÙÀÌ¿À 'SDÃø Á¶Ã¢¼±' °øµ¿ ´ëÇ¥ÀÌ»ç ¼±ÀÓ
SK¹ÙÆÊ, Áß±¹ ÇÕÀۻ翡 ÅëÁõ½Å¾à ±â¼úÀÌÀü...°è¾à±Ý 42¾ï
Ŭ¸³½ººñ¿£¾¾, BMI ÇÏÀÌÅ彺ÁÖ100´ÜÀ§ PMS °úÁ¦ ¼öÇà
¼ºµ¿±¸¾à, ÇѾ౹ °³¼³ µû¸¥ ÀÚÀ²ÁöµµÁ¡°Ë °È
ÃÖ±¤ÈÆ ´ë¾àȸÀå, ´ö¼º¾à´ë¼ '¾à»çÀÇ »çȸÀû ¿ªÇÒ' Ư°
'¾à±¹ ¾à¹°Çаú OTC' ÈÞº£À̽º ÈÞÄ®¸®Áö, ½ÃÁð2 ½ÃÀÛ
"¾àÇÐÀÇ ¹àÀº ¹Ì·¡ ºÃ´Ù"...1500¸í ¸ô¸° ¾àÇÐȸ Çмú´ëȸ
Ãæ³²¸¶Åð, À¯°ü±â°ü°ú ¸¶¾à·ù ¿À³²¿ë ¿¹¹æ ȸÀÇ
'¾à±¹ ¾à¹°Çаú OTC' ÈÞº£À̽º ÈÞÄ®¸®Áö, ½ÃÁð2 ½ÃÀÛ
"¾àÇÐÀÇ ¹àÀº ¹Ì·¡ ºÃ´Ù"...1500¸í ¸ô¸° ¾àÇÐȸ Çмú´ëȸ
Ãæ³²¸¶Åð, À¯°ü±â°ü°ú ¸¶¾à·ù ¿À³²¿ë ¿¹¹æ ȸÀÇ
°æ½Ç·Ã "±¹È¸, ÀÇ´ëÁõ¿ø ±¸°æ¸»°í °ø°øÀÇ´ë¹ý ó¸®Ç϶ó"
¼¿ï °¼±¸¾à, ¿¬¼ö±³À°¡¤ÀåÇÐȸ µî »ó¹Ý±â ÀÏÁ¤ È®Á¤
´Ý±â
¾ÈÀü¿ø, ÀνºÅ¸±×·¥ 'º½³¯ÀÇ ¿Ã½¼ ±×¸®±â' À̺¥Æ®
"Àΰø´«¹°, ´Ù¸¥ ¾È¾àÀ̶û »ç¿ëÇÏ·Á¸é 5ºÐ °£°Ý À¯Áö"
½Ä¾àó, '¿¥¾ÆÀÌÇÇ¿¤¿¡ÀÌ' Àӽø¶¾à·ù ÁöÁ¤ ¿¹°í
½Ä¾àó, ÀǾàÇ°¡¤ÀǾà¿ÜÇ° ºÒ¹ý Ç¥½Ã¡¤±¤°í ÁýÁßÁ¡°Ë
Áö³ÇØ 4ºÐ±â Á¦¾à»ê¾÷ ½Å±Ô ÀÏÀÚ¸® 480°³ âÃâ
´Ý±â
µ¿È¾àÇ°, ¹ÚÁø °øÀåÀå ¼±ÀÓ¡¦"Ç°Áú Çâ»ó ÁÖ·Â"
"½Å¼±ÇÑ ±â¸§ '³ëÀ¯ÆÄ'·Î °Ç°À» °ü¸®Çϼ¼¿ä"
À¯ÇѾçÇà ÀÚȸ»ç À̹ÿ½þÆ, ±â¼ú¼ºÆò°¡ Åë°ú
´ë¿õ '³ªº¸Å¸' ¹ß¸Å 10Áֳ⡦¹Ú¼º¼ö ½ÅÀÓ´ëÇ¥, ·Îµå¸Ê ¹ßÇ¥
Æĸ¶¸®¼Ä¡, ŹÝÁÖ»ç 'JBPÇöó¸óÁÖ' Â÷º°Á¡ ¼Ò°³
´Ý±â
°æ½Ç·Ã "±¹È¸, ÀÇ´ëÁõ¿ø ±¸°æ¸»°í °ø°øÀÇ´ë¹ý ó¸®Ç϶ó"
¼¿ï °¼±¸¾à, ¿¬¼ö±³À°¡¤ÀåÇÐȸ µî »ó¹Ý±â ÀÏÁ¤ È®Á¤
¾à»çȸ, ÀÌ´ë °³±¹µ¿¹®È¸ ½ÅÀÓ ÁýÇàºÎ¿Í Çù·Â ¾à¼Ó
°£Çù, ÀÇ·á°ø¹é ÇؼÒ...°¡Äª Àü´ã°£È£»ç ¾ç¼º ¹ÚÂ÷
¼º³²½Ã¾à, ³»´Þ 19ÀÏ ÄÚ¿¢½º¼ ¾à»ç¿¬¼ö±³À°
´Ý±â
¾Ë¸² ¡¤ °øÇ¥
±³À° ¡¤ °ÁÂ
¾à±¹»ó´ã¼Ò
Á¢¼ö ¡¤ ¹®ÀÇ
¾Ë¸²
¸®Å¥´ý TVCF ·±Äª ±â³ä ÃʹÐÂø ÄûÁî Ç®±â GO¢º
¾Ë¸²
ÀÌÈ¿©´ë ÀÓ»ó¹ÙÀÌ¿ÀÇコ ¿Â¶óÀÎ ÇÐÀ§°úÁ¤½Åû GO¢º
¾Ë¸²
¿¹½ºÅ² ¿ÀºÐ¾ÖÆ÷¸£Å× À̺¥Æ® Âü¿©Çϱâ
¾Ë¸²
[3RÄÚ¸®¾Æ]ICT ±ÔÁ¦»÷µå¹Ú½º ½ÇÁõ Ư·Ê ½ÂÀÎ!! ¼³Ä¡ ¹× ...
¾Ë¸²
Á¦ 9ȸ ´ÚÅ;ØÆÊ °³±¹ ¼¼¹Ì³ª 4¿ù 28ÀÏ(ÀÏ) GO¢º
¾Ë¸²
¹«Á» º£Å׶ûÀÇ ¹«Á» üÆ÷ ÀÛÀü 8OOOP ¢ºGO
D-255
[ÆÊŬ·¡½º]Àü°Á ¹«Á¦ÇÑ ½Ãû! (Ç×½ÃÁ¢¼ö) ( ~12.31 )
D-255
[ÆʽºÅ͵ð]ij³ª´Ù ¾à»ç ÀÚ°ÝÁõ[Ç×½ÃÁ¢¼ö] ( ~12.31 )
D-255
[ºÒ±³°øºÎ] ºñ´ë¸é ȸ¿ø ¸ðÁý GO¢º ( ~12.31 )
D-1
ÀÚÇÏ»ý·Â ½ÉÆ÷Áö¾ö¼¿ï 4¿ù 21ÀÏ(ÀÏ) GO¢º ( ~4.21 )
D-255
Á¦ 9ȸ ´ÚÅ;ØÆÊ °³±¹ ¼¼¹Ì³ª 4¿ù 28ÀÏ(ÀÏ) GO¢º ( ~12.31 )
D-1
ÀÌ´ë ÀÓ»ó¹ÙÀÌ¿ÀÇコ ÇÐÀ§°úÁ¤ GO¢º ( ~4.21 )
¼¼¹«»ó´ã
¾à±¹ °³¾÷ ¿¹Á¤ÀÔ´Ï´Ù. ±Ç¸®±ÝÀÇ ¼¼¹«Ã³¸® ¹®ÀÇÇÕ
¾à±¹°æ¿µ°ú â¾÷
¾à±¹ °£ÆÇ °¡°ÝÀÌ Ãµ¾çÁöÂ÷ÀÔ´Ï´Ù. µðÀÚÀÎ °£ÆÇÀÌ
¼¼¹«¡¤³ë¹«
±¹¹Î¿¬±Ý
¾à»ç´ëÃâ
°³±¹ ÀÚ±Ý ¹®Àǵå·Á¿ä
¾à»ç½Å¿ë´ëÃâ
Ãß°¡ ´ëÃâ ¹®Àǵ帳´Ï´Ù
¾à±¹ÈÀåÇ°
Æ°»ìÅ©¸² ¹®ÀÇ
¹ý·ü»ó´ã
¾à±¹°³¼³ÀÚ ÁöÀ§½Â°è¿¡ ´ëÇؼ ±Ã±ÝÇÑ Á¡ÀÌ ÀÖ½À´Ï
±³À° °Á ¹× ¾Ë¸² ±¤°í ¾È³» ÆäÀÌÁö
¿¬¼ö, ±³À°, ¼¼¹Ì³ª, Çмú°Á ¹× ±â¾÷±³À°, ¸ðÁý
°øÇ¥, Åä·Ðȸ, ÀǾàÇ° º¯°æ ¾È³» ¹× °¢Á¾ Çà»ç
¾Ë¸² ±¤°í¸¦ Çص帳´Ï´Ù.
(Á¢¼ö ¹®ÀÇ ¹Ù·Î°¡±â)
µ¥Àϸ®ÆÊ ´Üµ¶
Á¦¾à»ç´Â ¾î¶»°Ô ¹ß»ç¸£Åº ±¸»ó±Ý ¼Ò¼Û µÚÁý¾ú³ª
'ÀÚ´©ºñ¾Æ' ³Ñ±ä Çѱ¹MSD »ç¾÷ºÎ Ãà¼Ò¡¦Èñ¸ÁÅðÁ÷ ½Ç½Ã
Á¦¾à, »êÀںΡ¤±âÀçºÎ¿¡ "Åå½Å ±¹°¡Çٽɱâ¼ú ÇØÁ¦¸¦"
´ç´¢º´¾à ÀÚ´©ºñ¾Æ ºÒ¼ø¹° °ËÃ⡦ÀϺΠÁ¦Ç° ȸ¼ö
Àü¹®¾à»ç ÃÖÁ¾¾È 'Áö¿ª»çȸ¾à·á¡¤ÀǾàÁ¤º¸' °á±¹ ºüÁ®
³ì½ÊÀÚ, 1200¾ï Ç×Ç÷¼ÒÆÇÁ¦ 'Çöóºò½º' °°ÀÌ ÆÇ´Ù
'À¯Åë °ø·æ' Áö¿À¿µ ´õ Ä¿Áö³ª...2À§ ¹éÁ¦ ÁöºÐ ¸ÅÀÔ ÃßÁø
´ëÇÐ Çõ½Å½Å¾àÇаú ½Å¼³ ÃßÁø...»ê¾÷¾à»ç ÀÔÁö Èçµé?
³ì½ÊÀÚ, GSK »õ ´ë»óÆ÷Áø ¹é½Å '½Ì±×¸¯½º' °°ÀÌ ÆÇ´Ù
´ë¿õÁ¦¾à SGLT-2 ´ç´¢ ½Å¾à '¿£ºí·Î' ¸íÂû ´Þ¾Ò´Ù
Dailypharm KOREA
Breast cancer Tx Ibrance¡¯s AE rate at 86%...6yr PMS results
Xospata makes progress for reimb...up for DREC review
Scemblix is listed in July
IND of LegoChem Bio's ADC was approved by the FDA
Expansion of indications for Forxiga as a treatment for HFrE
ÆʼîÇθô
ÀǾàÇ°¸ô
Çコ¿ëÇ°¸ô
±âŸ»óÇ°¸ô
Àϼº½Å¾à
¸ÞµðÄ«ÄÚ¸®¾Æ
¿¥¿¡ÇÁ¾¾
À¯´Ï¸Þµå
Àϼº½Å¾à
Ç÷ç¾ÆµåÄõµå
¸ÞµðÄ«ÄÚ¸®¾Æ
ÃÊÀÓ°è¾ËƼÁö
¶ó¿ÂÆĸ¶
Çdzª¿ÂÁ¤
À¯´Ï¸ÞµåÁ¦¾à
¸ÞµðÆʸô
¸ÞµðÄ®Çö´ë
¸¶´õ½ºÁ¦¾à
´õÆÊÀÌÁö¹Ù¿ï
¸¶½ºÅÍ
¹ÙÀÌÅ©·Ò°£À¯»ê±Õ
¸¶´õ½ºÁ¦¾à
ÄÜƼ600
À¯´Ï¸ÞµåÁ¦¾à
À¯´Ïµ§Å»¿ÃÄɾîÄ¡¾à
¿¹½ºÅ²
¿ÀºÐ¾ÖÆ÷¸£Å×
¿¥¿¡ÇÁ¾¾
¾Æ·Î´Ï¾Æ´Ü¹éÁú¹Ù
ÈÞº£À̽º
KnH¸ÞµðÅØ
°æ¹æ½Å¾à
¸Þµð¶óÀÌÇÁ
ÂøÇѳª¹«ÀÎÅ׸®¾î
³»¼Õ¾ÈÀÇ ¾à±¹
´ÚÅ;ØÆÊ
¾à»ç ½Å¿ë´ëÃâ
¼±ÅÃÀÇ ÆøÀ̳оîÁø ¾à±¹Ã¼ÀÎ
°æ¹æ½Å¾à
°æ¿Á°í
¾à»ç¸¦ À§ÇÑ ¾à±¹ Ç÷§Æû
¾à±¹ÀÎÅ׸®¾î
¾à»ç´Ô ÀÔ¼Ò¹®
¾à±¹»ó´ã¼Ò
¾à»ç´ëÃâ
¼¼¹«»ó´ã
¹ý·ü»ó´ã
¾à»ç½Å¿ë´ëÃâ
¾à±¹ÈÀåÇ°
¼¼¹«¡¤³ë¹«
¾à±¹°æ¿µ
¹ý·ü»ó´ã
¾à±¹°³¼³ÀÚ ÁöÀ§½Â°è¿¡ ´ëÇؼ ±Ã±ÝÇÑ Á¡ÀÌ ÀÖ½À´Ï´Ù,,,
- ¹ý¹«¹ýÀÎ ±Ô¿ø -
¾à»ç½Å¿ë´ëÃâ
Ãß°¡ ´ëÃâ ¹®Àǵ帳´Ï´Ù
- ±è´ë°Ç ½ÇÀå -
¼¼¹«»ó´ã
¾à±¹ °³¾÷ ¿¹Á¤ÀÔ´Ï´Ù. ±Ç¸®±ÝÀÇ ¼¼¹«Ã³¸® ¹®ÀÇÇÕ´Ï´Ù.
- ±èÇåÈ£ ¼¼¹«»ç -
¾à»ç´ëÃâ
°³±¹ ÀÚ±Ý ¹®Àǵå·Á¿ä
- ±è¼ºÈñ ´ëÇ¥ -
¾à±¹°æ¿µ°ú â¾÷
¾à±¹ °£ÆÇ °¡°ÝÀÌ Ãµ¾çÁöÂ÷ÀÔ´Ï´Ù. µðÀÚÀÎ °£ÆÇÀÌ Áß¿äÇÑ°¡¿ä?
- ±èÇöÀÍ ¾à»ç -
¾à±¹ÈÀåÇ°
Æ°»ìÅ©¸² ¹®ÀÇ
- ±è¿µ¼± ¾à»ç -
¼¼¹«¡¤³ë¹«
±¹¹Î¿¬±Ý
- ÀÓÇö¼ö ´ëÇ¥ -
±âȹ¡¤Å½»ç
±âȹ
ºÐ¼®
ÇöÀå
Çؼ³
DPÃÊ´ë¼®
¹Ì·¡Æ÷·³
Ä«µå´º½º
À¥Å÷º¹¾àÁöµµ
¿©±ä µÇ°í, Àú±ä ¾È µÇ°í¡¦°³ºÀ ¸¶¾à¡¤ÇâÁ¤¾à ¹ÝÇ° ³í¶õ
ÀþÀº¾à»ç, ¼ÒºÐ °Ç±â½Ä °ü½É...¸ÅÃâ ´Ù°¢È ±âȸµÉ±î
Àü¿ë °Ç±â½Ä ¿Ç³¡¦¾à±¹ °Ç±â½Ä ¾÷üµé ¶§¾Æ´Ñ ȰȲ
Àü¹®¾à»ç¡¤·Îº¿ Çù¾÷½Ã´ë ¿Â´Ù...¾à¹« °íµµÈ ºÐ±âÁ¡
¿ÀÇǴϾð
Àü¹®°¡Ä®·³
µ¥½ºÅ©½Ã¼±
Ưº°±â°í
±âÀÚ¼öø
[±âÀÚÀÇ ´«] ¾àÁ¤¿ø ¿î¿µ ÇÁ·Î±×·¥ÀÌ ºÒ¾ÈÇÏ´Ù
°Çý°æ ±âÀÚ
[µ¥Àϸ®ÆÊ=°Çý°æ ±âÀÚ] PPDSºÎÅÍ ¾à±¹Ã»±¸SW±îÁö, ¾àÇÐÁ¤º¸¿øÀÌ ¿î¿µÇÏ´Â ¾à±¹ ÇÁ·Î±×·¥ÀÇ ¿À·ù°¡ À̾îÁö¸é¼ ¾à»çµéÀÇ ºÒÆí°ú ºÒ¸¸ÀÌ °íÁ¶µÇ°í ÀÖ´Ù. ÀÏ°¢¿¡¼´Â À۳⠸» ³×Æ®¿öÅ© ¿À·ù·Î ÀÎÇØ ¸ÔÅëÀÌ µÈ...
[±âÀÚÀÇ ´«] ¾à±¹ ÀÏ¹Ý¾à ³¸Å¿Í Â÷º°È Àü·«
Á¤ÈïÁØ ±âÀÚ
[µ¥½ºÅ© ½Ã¼±] ºÒ¼ø¹° ¼Ò¼Û°ú Á¤Ã¥ ¹Ý¼º
õ½ÂÇö ±âÀÚ
[±âÀÚÀÇ ´«] GMP Ãë¼Ò óºÐ°ú ¾ö¹úÁÖÀÇÀÇ ÇÑ°è
±èÁø±¸ ±âÀÚ
ÆʾÆÄ«µ¥¹Ì
Á¦Ç°°ÁÂ
Çмú°ÁÂ
°æ¿µ°ÁÂ
OTC»ó´ã Àü¹®°¡°úÁ¤
'ȯÀÚ¿¡°Ô ²À ¸Â´Â ¾Æ¸£±â´Ñ ¼±Åùý'
'NSAIDs + Ç÷·ù°³¼±À¸·Î ¹¶Ä£ ÅëÁõ ¿ÏÈ!'
'È°¼ººñŸ¹Î 3Á¾¿¡ ¸é¿ª°È ¹Ì³×¶ö±îÁö MAX'
'¿Ã¹Ù¸¥ »óó¿Í È»ó°ü¸® ¹æ¹ý!'
ÆÊTV
ÆÊÅäÅ©
À̽´¿µ»ó
ºÎÀÛ¿ë ¸®Æ÷Æ®
OTC¼¿¸µÆ÷ÀÎÆ®
½ºÆ¿ÄÆ¿µ»ó
½ºÅ×·ÎÀ̵å Àå±â»ç¿ë ºÎÀÛ¿ë°ú ¾à±¹ »ó´ã¹ýÀº?
ºñ´ë¸é¡¤¾à¹è¼Û¡¤¾à°¡¡¤°Çº¸±îÁö...Á¤Ã¥ ÃßÁø Ÿ°Ý ºÒ°¡ÇÇ
µ¿¼ºÁ¦¾à ±¤°ú¹ÎÁ¦ Æ÷³ëÁ¨, ±Û·Î¹ú Çõ½Å½Å¾à µµÀü
¾Ë¸®ÄÚÁ¦¾à, ¸Å³â ¼ºÀåÇϴ ȸ»ç¡¦°æ·ÂÁ÷ À§ÁÖ Ã¤¿ë
Á¤Ã¥°ú ¹ý·ü
°Ç°º¸Çè
ÀǾàÇ°
ÀǷᡤ¾à¹«
¹ý·É
Á¤ºÎ, ±¹¸³´ë °ÇÀÇ ¼ö¿ë °¡´Ú¡¦ÀÇ´ë Áõ¿ø Ãà¼ÒµÉ µí
ÀÌÁ¤È¯ ±âÀÚ
[µ¥Àϸ®ÆÊ=ÀÌÁ¤È¯ ±âÀÚ] Á¤ºÎ°¡ ÀÇ°ú´ëÇÐ Á¤¿ø Áõ¿ø ±Ô¸ð¸¦ ÀϺΠÁ¶Á¤ÇÒ ¼ö ÀÖ°Ô ÇØ´Þ¶ó´Â ±¹¸³´ë ÃÑÀåµéÀÇ °ÇÀǸ¦ ¼ö¿ë, ³»³âµµ Áõ¿ø ±Ô¸ð 2000¸íÀ» Ãà¼ÒÇÏ´Â ÂÊÀ¸·Î Á¤Ã¥ ¹æÇâÀ» Àâ´Â ºÐÀ§±â´Ù. Á¤ºÎµµ...
"A9 ¸ðµÎ µîÀçµÈ ¿¢½ºÆ÷ºñ¿À, ±¹³» Á¶¼ÓÈ÷ µîÀçµÅ¾ß"
±èÁ¤ÁÖ ±âÀÚ
'¿£Å¸Ä«Æù' ´ÜÀÏÁ¦ ºÒ¼ø¹° °ËÃâ...¾ÈÀüÁ¶Ä¡ °ËÅä Âø¼ö
°½Å±¹ ±âÀÚ
½Ä¾àó, ÀÓ»ó½ÃÇè ±â°ü È®´ë...Áö¿ªÀÇ·á±â°ü Âü¿© °ËÅä
ÀÌÇý°æ ±âÀÚ
¿ø¹®ÀÚ·á
Àüü
|
ÇàÁ¤
|
Á¦¾à
|
º¸µµ
|
¾à»ç
|
ÀÇ·á
|
[ÇàÁ¤]
¾Ï·ÎµðÇɺ£½Ç»ê¿° ´ÜÀÏÁ¦ Ç°¸ñ
[ÇàÁ¤]
´ÏÆ®·Î»ç¹Î·ù ºÒ¼ø¹° 1ÀÏ ¼·ÃëÇã¿ë·®
[ÇàÁ¤]
ÀǾàÇ° Á¤º¸ ÀüÀÚÀû Á¦°ø ´ë»ó ÀǾàÇ°
[Á¦¾à]
(¡¯24.3.1 Àû¿ë) 948°³ Ç°¸ñ(º¸Çè¾à°¡
[ÇàÁ¤]
2022³â ÁöÃ⺸°í¼ °á°ú
Á¦¾à¡¤¹ÙÀÌ¿À
±â¾÷
R&D¿Í ¾à¹°
Çã°¡¿Í ƯÇã
À¯Åë°ú ¸¶ÄÉÆÃ
Á¦¾à´Üü
"°¡¶àÀ̳ª Èûµçµ¥"¡¦CRO, ÀÇ·á°ø¹é Àå±âÈ¿¡ '¹ß µ¿µ¿'
±èÁø±¸ ±âÀÚ
[µ¥Àϸ®ÆÊ=±èÁø±¸ ±âÀÚ] ÀÇ´ë Áõ¿øÀ» µÑ·¯½Ñ ÀÇ¡¤Á¤ °¥µîÀ¸·Î ÀÇ·á°ø¹éÀÌ Àå±âÈÇÏ´Â °¡¿îµ¥, ÀÓ»ó½ÃÇè ¼öŹ ¾÷üµéÀÇ °í¹ÎÀÌ ±í¾îÁö°í ÀÖ´Ù. Àü°øÀǵé°ú ÀϺΠÀÇ´ë ±³¼ö°¡ ÀÇ·áÇöÀåÀ» ¶°³ ÀÌÈÄ·Î ÀÓ»ó½ÃÇè¿¡ ...
ÀÓÁ¾À± °øµ¿´ëÇ¥ 'ÀÇ·áÇõ½ÅÀ§¿øȸ' ù ¼¼¹Ì³ª °³ÃÖ
±èÁø±¸ ±âÀÚ
µ¿¼ºÁ¦¾à, º£Æ®³² ÇϳëÀÌ ºäƼÄÉ¾î ¿¢½ºÆ÷ Âü°¡
À̼®ÁØ ±âÀÚ
¾¾Æ¼¾¾¹ÙÀÌ¿À 'SDÃø Á¶Ã¢¼±' °øµ¿ ´ëÇ¥ÀÌ»ç ¼±ÀÓ
À̼®ÁØ ±âÀÚ
[±âÀÚ Àü¹® ÄÚ³Ê]
"õÆíÀÏ·üÀû ¾à±¹Àº ½È¾î"¡¦ÁøÈÇÏ´Â ÀΡ¤ÀͽºÅ׸®¾î
[Á¦¾à¡¤¹ÙÀÌ¿À ±â¾÷ºÐ¼®]
½Å»ç¾÷ ÁøÃ⡤CMO È®´ë...´ë¿õ¹ÙÀÌ¿À, ±ÔÁ¦°È Á¤
º´¿ø¡¤¾à±¹
ÀǾà´Üü
»ê¾÷°ú °æ¿µ
ºÎµ¿»ê¡¤¼¼¹«
»ç°Ç°ú ¼Ò¼Û
¾àÇС¤Çмú
½Å¼³ Çõ½Å½Å¾àÇаú ÇѾç´ë À¯·Â...±³À°ºÎ ÀÌ´Þ ¹ßÇ¥
Á¤ÈïÁØ ±âÀÚ
[µ¥Àϸ®ÆÊ=Á¤ÈïÁØ ±âÀÚ] ±³À°ºÎ°¡ ÀÌ´Þ Çõ½Å½Å¾àÇаú ½Å¼³ ´ëÇÐ ¹ßÇ¥¸¦ ¾ÕµÎ°í ÀÖ´Â °¡¿îµ¥, ÇѾç´ëÇб³ ¼±¹ßÀÌ À¯·ÂÇÑ °ÍÀ¸·Î ¾Ë·ÁÁ³´Ù. ¾àÇа迡 µû¸£¸é ½Åû¼¸¦ Á¦ÃâÇÑ ÀϺΠ´ëÇÐÀÌ ±³À°ºÎ·ÎºÎÅÍ ¼±Á¤ ...
¼ºµ¿±¸¾à, ÇѾ౹ °³¼³ µû¸¥ ÀÚÀ²ÁöµµÁ¡°Ë °È
°Çý°æ ±âÀÚ
ÃÖ±¤ÈÆ ´ë¾àȸÀå, ´ö¼º¾à´ë¼ '¾à»çÀÇ »çȸÀû ¿ªÇÒ' Ư°
°Çý°æ ±âÀÚ
'¾à±¹ ¾à¹°Çаú OTC' ÈÞº£À̽º ÈÞÄ®¸®Áö, ½ÃÁð2 ½ÃÀÛ
°Çý°æ ±âÀÚ
¾à±¹ ÀÏ¹Ý¾à ¸ÅÃâ¾× Top 100(04¿ù)
¼øÀ§
»óÇ°¸í
Ƚ¼ö
¼ö·®
ÆǸűݾ×
1
ŸÀÌ·¹³îÁ¤500mg(10Á¤)
24985
34136
106,254,903¿ø
2
±î½ºÈ°¸í¼öÅ¥¾×
12650
78116
91,557,701¿ø
3
ÆÇÄÝ¿¡½º³»º¹¾×
12951
92459
77,241,400¿ø
4
ÆÇÇǸ°Å¥¾×
10544
88580
70,277,803¿ø
5
³ë½ºÄ«³ª°Ö 20g
2437
2538
51,905,903¿ø
6
¾ÖÅ©³íÅ©¸²
4449
4675
51,612,401¿ø
7
¾Æ·Î³ª¹Î°ñµåÇÁ¸®¹Ì¾ö(120Á¤)
999
1513
51,474,000¿ø
8
º¥Æ÷º§S¿¡½ºÁ¤
788
1388
47,969,900¿ø
9
ºñÆÇÅÙ¿¬°í 30g
3811
6819
45,186,300¿ø
10
Ź¼¾ ¿¬Áúĸ½¶(10ĸ½¶)
11527
17095
45,072,200¿ø
11
ÄÝ´ë¿ø ÄÚÇÁÅ¥½Ã·´
8628
11022
40,955,500¿ø
12
ÀÌ°¡Åº¿¡ÇÁĸ½¶(60ĸ½¶*3)
1409
2147
40,544,100¿ø
13
ÄÉÅäÅéÇöó½ºÅ¸(34¸Å)
2805
4526
40,492,300¿ø
14
ÄÉÅäÅéÇöó½ºÅ¸(40¸Å)
2403
3030
40,002,000¿ø
15
ÅÙÅÙÃòÁ¤(120Á¤)
1518
5769
38,491,900¿ø
16
ÀÕÄ¡ÆäÀ̽ºÆ®Ä¡¾à120g
2616
3632
36,739,700¿ø
17
Å׶óÇÃ·ç ³ªÀÌƮŸÀÓ
3475
4335
35,012,300¿ø
18
ÅÙÅÙÃòÁ¤(10Á¤)
11323
19348
34,717,803¿ø
19
ŸÀÌ·¹³îÁ¤500mg(30Á¤)
3326
5679
33,780,830¿ø
20
º£³ªÄ¡¿À¿¡ÇÁ¾×75ml
7665
38247
33,747,100¿ø
21
µÑÄÚ¶ô½º-¿¡½ºÀå¿ëÁ¤(40Á¤)
1840
5375
30,736,900¿ø
22
¾Æ·º½º´ëÇü
4037
9663
29,918,494¿ø
23
±¤µ¿°æ¿Á°í
283
8696
29,842,555¿ø
24
°Ôº¸¸°Á¤
5430
9138
29,301,600¿ø
25
±¤µ¿¿ìȲû½É¿øÇöŹ¾×50ml(õ¿¬»çÇâ)
1271
2502
28,521,003¿ø
26
ÈĽõò¿¬°í10g
3465
3786
27,534,640¿ø
27
ÀÕÄ¡ÆäÀ̽ºÆ®ÇÇÅæÄ¡µå150g
1573
2006
26,889,260¿ø
28
µ¿¾ÆD-ÆÇÅ׳°í
2508
2696
26,618,925¿ø
29
ÀÌÁö¿£6À̺ê(30ĸ½¶)
2976
3586
25,721,250¿ø
30
¾Æ·Î³ª¹Î°ñµå(100Á¤)
766
1815
25,552,700¿ø
31
ÄÝ´ë¿ø ÄݵåÅ¥½Ã·´
5407
7015
25,122,860¿ø
32
ºñ¸Æ½º¸ÞŸºñ
413
767
24,955,960¿ø
33
ÈĽõò¿¬°í5g
4254
4725
24,906,000¿ø
34
¿ÀÅ¥½Ã½ºÁ¡¾È¾×0.5ml*60°³
1353
1594
24,770,400¿ø
35
Å׶óÇ÷ç Äݵå&ÄÚÇÁ ³ªÀÌÆ®
1756
2032
24,491,400¿ø
36
¸ðµåÄÝ¿¡½º
6059
9477
24,262,080¿ø
37
±¤µ¿¿ìȲû½É¿øȯ(»çÇâ)
256
1814
24,145,000¿ø
38
¸¶µ¥Ä«¼ÖÄɾ°í10g
3276
3666
24,032,500¿ø
39
±¤µ¿¿øÅÁ
6311
25152
23,772,414¿ø
40
ÄÉÆèÇöó½ºÅ¸
3905
9436
23,752,900¿ø
41
ºñ¸Æ½ºÁ¦Æ®Á¤
248
448
23,676,000¿ø
42
¾ÖÅ©¸°°Ö
1734
1784
21,177,601¿ø
43
Áö¸£ÅØÁ¤
3542
4728
22,617,801¿ø
44
¸¶±×ºñ½ºÇǵå¾×
1691
10632
22,384,404¿ø
45
±¤µ¿¿ìȲû½É¿øÇöŹ¾×50ml(¿µ¹¦Çâ)
1641
3987
22,096,501¿ø
46
Àλ絹Ç÷¯½º(100Á¤)
639
1747
21,531,100¿ø
47
ÄÝ´ë¿øÅ°Áî³ëÁî¿¡½º½Ã·´
4528
6014
21,187,200¿ø
48
¸Ó½Ã·ÐÁ¤
1901
2431
20,749,100¿ø
49
¸¶±×ºñ¸Æ½º¿¬Áúĸ½¶
399
658
20,035,000¿ø
50
ÄÚ¾ØÄ𠳪Àß½ºÇÁ·¹ÀÌ
1747
2009
19,733,200¿ø
51
ÇÁ·»Áî¾ÆÀ̵å·ÓÁ¡¾È¾×ÄðÇÏÀÌ ¾÷14ml
3076
3382
19,545,800¿ø
52
ÇÁ·»Áî¾ÆÀ̵å·ÓÁ¡¾È¾×Äð ¾÷14ml
3132
3365
19,407,700¿ø
53
³ë½ºÄ«³ª°Ö10g
1562
1575
19,367,200¿ø
54
ŸÀÌ·¹³î8½Ã°£À̾˼¹æÁ¤
4621
6604
18,844,000¿ø
55
Ä«¸®ÅäÆ÷ÅÙ¿¬Áúĸ½¶(60ĸ½¶)
419
456
18,655,500¿ø
56
Àλ絹Ç÷¯½º(270Á¤)
239
781
18,548,700¿ø
57
¾Æ·º½ºÁßÇü
3729
6051
18,478,900¿ø
58
¹éÃʽ÷´Ç÷¯½º
2723
3479
18,063,600¿ø
59
ÀÌÁö¿£6À̺꿬Áúĸ½¶
4955
6692
17,439,900¿ø
60
ÇÁ·»Áî¾ÆÀ̵å·ÓÁ¡¾È¾×¼ø ¾÷14ml
2699
2932
17,011,201¿ø
61
¿ÀÆ®¸®ºó¸àÅç0.1%ºÐ¹«Á¦
1376
1734
17,005,400¿ø
62
ºñ¸Æ½º¸ÞŸÁ¤(60Á¤*2)
326
713
16,449,010¿ø
63
¿ë°¢»êÄð°ú¸³(º¹¼þ¾ÆÇâ,18Æ÷)
2018
2757
16,421,300¿ø
64
´ÏÄÚ·¹Æ®² 2mg (Äð¹ÎÆ®Çâ)
710
1877
16,372,700¿ø
65
½ºÆ®·¾½ÇÆ®·ÎÅ°Çã´Ï&·¹¸ó
2292
3595
16,271,800¿ø
66
¾ÈƼǪ¶ó¹ÎÄðīŸÇö󽺸¶(5¸Å)
2938
5484
16,171,700¿ø
67
ÄÝ´ë¿øÅ°ÁîÄÚÇÁ½Ã·´
3479
4173
16,000,100¿ø
68
´ë¿õ¿ì·ç»ç¿¬Áúĸ½¶(120ĸ½¶)
402
535
15,781,800¿ø
69
¸¶µ¥Ä«¼ÖÄɾ°í 6g
3254
3525
15,766,500¿ø
70
Ä¡¼¾Ä¸½¶(60ĸ½¶)
545
1496
15,761,600¿ø
71
Ź¼¾·¹À̵ð
3343
4248
15,631,100¿ø
72
¸®¾ÈÁ¡¾È¾×
775
874
15,453,900¿ø
73
Ä¡¼¾Ä¸½¶(120ĸ½¶)
313
323
15,423,000¿ø
74
Àλ絹(100Á¤)
494
1019
15,196,000¿ø
75
¿ëÇ¥¿ìȲû½É¿ø¾× 50ml
1338
3903
15,156,147¿ø
76
ÄÚ¸ÞÅ°³ªÄ¸½¶
2709
3397
15,057,200¿ø
77
À¯ÇѺñŸ¹ÎCÁ¤1000mg
794
2720
14,993,707¿ø
78
¾ÈƼǪ¶ó¹Î ´õºíÆÄ¿ö ÁßÇü
2333
5998
14,588,300¿ø
79
°ÖÆ÷½º¿¤
1926
2465
14,522,000¿ø
80
±¤µ¿½ÖÈÅÁ
4170
17914
14,381,745¿ø
81
Á¶¾ÆÆË(10¸Å)
1881
2929
14,321,331¿ø
82
°ÖÆ÷½º¿¥ÇöŹ¾×
2436
3508
14,265,400¿ø
83
¸¶±×ºñ½ºÇÇµå ´õºí¾×¼Ç
836
4370
14,196,502¿ø
84
Ź¼¾ ¿¬Áúĸ½¶(30ĸ½¶)
1650
2635
14,116,500¿ø
85
ÈѽºÅ»Ç÷¯½º
3324
4912
14,031,100¿ø
86
´ºº£Àξ×
555
5307
14,019,700¿ø
87
½ºÆ¼¸ð¸°¿¡½ºÅ©¸²10g
1528
1631
13,828,600¿ø
88
ÄÝ´ë¿øÅ°ÁîÄݵå½Ã·´
2500
2882
13,691,900¿ø
89
¸ñ¾Ø½ºÇÁ·¹ÀÌ
1320
1381
13,649,800¿ø
90
¿ëÇ¥¿ìȲû½É¿ø¾×50ml(õ¿¬»çÇ⺯¹æ)
737
1363
13,641,300¿ø
91
ºñÆÇÅÙ¿¬°í 100g
523
544
13,388,900¿ø
92
º¹ÇÕ¿ì·ç»ç¿¬Áúĸ½¶(80ĸ½¶)
365
711
13,361,800¿ø
93
¼ÒÇÏÀÚÀÓÇ÷¯½ºÁ¤
3672
4334
13,206,834¿ø
94
´ÏÁ¶¶ö2%¾× 120ml
740
763
13,192,700¿ø
95
ŸÀÌ·¹³îÄݵ忡½º
2696
3899
13,106,300¿ø
96
ÄÚǪ½Ã·´¿¡½º
3204
4224
12,985,400¿ø
97
Å©¸°Å¬¸ê±Õ»ý¸®½Ä¿°¼ö20ml*20¾ÚÇÃ
1204
2376
12,975,500¿ø
98
ÀÌÁö¿£6ÇÁ·Î ¿¬Áúĸ½¶(30ĸ½¶)
1458
1614
12,866,950¿ø
99
ÄÝ´ë¿ø ³ëÁîÅ¥¿¡½º½Ã·´
2711
3348
12,819,100¿ø
100
ÄÚ¾Ø ³ªÀß½ºÇÁ·¹ÀÌ
1244
1322
12,767,500¿ø
Àüüº¸±â